MedTrace Logo

Seroquel in Bipolar Depression Versus Lithium

NCT00206141 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 672

Last updated 2013-01-04

No results posted yet for this study

Summary

This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to 52 with quetiapine fumarate (Seroquel) compared to placebo.

Conditions

Interventions

DRUG

Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Seroquel Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2007-05-31

Countries

  • Canada
  • Croatia
  • Estonia
  • Germany
  • Indonesia
  • Latvia
  • Lithuania
  • Malaysia
  • Norway
  • Philippines
  • Poland
  • Russia
  • Serbia
  • South Korea
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206141 on ClinicalTrials.gov